Metabolic profiling of gestational diabetes in obese women during pregnancy by White, Sara L. et al.
ARTICLE
Metabolic profiling of gestational diabetes in obese
women during pregnancy
Sara L. White1 & Dharmintra Pasupathy1 & Naveed Sattar2 & Scott M. Nelson3 &
Debbie A. Lawlor4,5 & Annette L. Briley1 & Paul T. Seed1 & Paul Welsh2 & Lucilla Poston1 &
on behalf of the UPBEAT Consortium
Received: 21 March 2017 /Accepted: 9 June 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Aims/hypothesis Antenatal obesity and associated gestational
diabetes (GDM) are increasing worldwide. While pre-existing
insulin resistance is implicated in GDM in obese women, the
responsible metabolic pathways remain poorly described. Our
aim was to compare metabolic profiles in blood of obese
pregnant women with and without GDM 10 weeks prior to
and at the time of diagnosis by OGTT.
Methods We investigated 646 women, of whom 198 developed
GDM, in this prospective cohort study, a secondary analysis of
UK Pregnancies Better Eating and Activity Trial (UPBEAT), a
multicentre randomised controlled trial of a complex lifestyle
intervention in obese pregnant women. Multivariate regression
analyses adjusted for multiple testing, and accounting
for appropriate confounders including study interven-
tion, were performed to compare obese women with
GDM with obese non-GDM women. We measured 163
analytes in serum, plasma or whole blood, including
147 from a targeted NMR metabolome, at time point
1 (mean gestational age 17 weeks 0 days) and time
point 2 (mean gestational age 27 weeks 5 days, at time
of OGTT) and compared them between groups.
Results Multiple significant differences were observed in
women who developed GDM compared with women without
GDM (false discovery rate corrected p values <0.05). Most
were evident prior to diagnosis. Women with GDM demon-
strated raised lipids and lipoprotein constituents in VLDL
subclasses, greater triacylglycerol enrichment across lipopro-
tein particles, higher branched-chain and aromatic amino
acids and different fatty acid, ketone body, adipokine, liver
and inflammatory marker profiles compared with those with-
out GDM.
Conclusions/interpretation Among obese pregnant women,
differences in metabolic profile, including exaggerated
dyslipidaemia, are evident at least 10 weeks prior to a diagno-
sis of GDM in the late second trimester.
Keywords Biomarkers . Gestational diabetes . Lipids .
Obesity . Pregnancy . Targetedmetabolome
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Introduction
Pregnancy is associated with profound changes in metabo-
lism, which facilitate the growth of a healthy fetus and prepare
the mother and infant for the energy requirements in the post-
partum period. After an initial anabolic stage, a physiological-
ly beneficial increase in insulin resistance enhances fetal avail-
ability of metabolic substrates [1]. In contrast, pre-pregnancy
insulin resistance, as often observed in obese women, has
been implicated in greater risk of gestational diabetes
(GDM) and associated fetal adversity [2].While the metabolic
response to pregnancy is recognised to be different in this
increasingly prevalent subgroup of the antenatal population
[1], the pathways to GDM in obese women remain poorly
described. This is of importance as less than one-third of obese
women develop GDM.
Insight into the metabolic adaptations to pregnancy and the
pathophysiology of complications is facilitated by metabolo-
mics technology, which provides reproducible analytical data.
Two recent metabolomic studies of normal pregnancy have
described widespread metabolic perturbations that extend be-
yond the traditional boundaries of insulin resistance to encom-
pass pathways including amino acids, lipoproteins and inflam-
matory markers [3, 4]. GDM has also been the focus of some
recent metabolomic studies, although to date all have included
participants from across the maternal weight spectrum, which
is itself known to affect the maternal metabolome [5–9]. None
has addressed the metabolome in obese women prior to and at
the time of GDM diagnosis.
As no distinction is currently made in clinical practice be-
tween obese women of lower and higher GDM risk, we re-
cently developed a prediction tool for GDM in obese women.
We found that an algorithm including clinical factors and
some conventionally measured biomarkers analysed early in
the second trimester of pregnancy performed well, although
the addition of more complicated metabolomic measures did
not augment the performance of the tool [10].
The aim of the present study was to identify differences in
metabolites associated with GDM at two time points in gesta-
tion in this cohort of obese women. We report on the early
second trimester metabolites, formerly not evaluated in detail,
as well as those measured at the time of diagnostic OGTT in
the late second trimester.
Methods
Study design This prospective cohort study was a secondary
analysis using data from the UK Pregnancies Better Eating
and Activity Trial (UPBEAT; isrctn.org registration number
89971375). UPBEAT was a multicentre RCT of a complex
dietary and physical activity intervention designed to prevent
GDM in obese women and reduce the incidence of large-for-
gestational-age (LGA) infants [11]. Women with a pre-
pregnancy diagnosis of diabetes, essential hypertension, renal
disease, systemic lupus erythematosus, antiphospholipid syn-
drome, sickle-cell disease, thalassaemia, coeliac disease, thy-
roid disease or current psychosis and those currently pre-
scribed metformin were excluded. The cohort comprised
1555 women recruited between 2009 and 2014; women were
>16 years of age, had a BMI ≥30 kg/m2 and a singleton preg-
nancy, and were randomised between 15 weeks 0 days’ and
18 weeks 6 days’ gestation (15+0 and 18+6) to either the be-
havioural intervention superimposed on standard antenatal
care or standard antenatal care. As the primary outcomes
(GDM and LGA infants) did not differ between intervention
and control arms, the trial was treated as a cohort for the
purposes of this study.
All aspects of the trial, including the analyses in the present
study, were approved by the National Health Service Research
Ethics Committee (UK Integrated Research Application
System; reference 09/H0802/5) and all participants, including
women aged 16 and 17 using Fraser guidelines, provided
informed written consent [11].
Participants This was a complete case analysis including
women who had undertaken a diagnostic OGTT, with blood
samples at trial entry and at the time of GDM testing, and with
complete analyte data at both time points (n = 646).
Procedures Sociodemographic, clinical and anthropometric
information and non-fasting (random) blood samples were
provided at time point 1 (15+0 to 18+6 weeks’ gestation).
The trial protocol required inclusion of OGTTs carried out at
27+0 to 28+6 weeks’ but for this study a clinically pragmatic
approach was adopted with OGTTs at 23+2 to 30+0 weeks’
(mean 27+5) included. Diagnosis of GDM was according to
International Association of Diabetes and Pregnancy Study
Groups (IADPSG) criteria (fasting glucose ≥5.1 mmol/l, 1 h
≥10.0 mmol/l and 2 h ≥8.5 mmol/l in response to a 75 g oral
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glucose load) [12]. At OGTT (time point 2), an additional
sample used for the analyses described below was obtained
at the time of the first fasting blood test (fasting ≥10 h). Blood
was kept on ice, processed within 2 h and stored at −80°C
(whole blood, serum and plasma). Analyses were undertaken
by laboratory technicians blinded to participant data.
Metabolic profilingA total of 163 analytes were evaluated in
plasma, serum or whole blood using a combination of an
NMRmetabolome and conventional laboratory assays at both
time points. A high-throughput NMR metabolomic platform
(serum) targeted to multiple pathways with relevance to insulin
resistance was employed (http://computationalmedicine.fi/,
accessed 10 January 2017) and analyses were carried out in
two batches. This NMR metabolite profile has been used for
many large-scale epidemiological studies [4, 13–17] and the
methodology has been described previously. There are no dis-
cernible batch effects [18]. The platform accurately quantifies
numerous lipid measures; lipoprotein particles include VLDL
subdivided into six subclasses (extremely large, very large,
large, medium, small, very small), IDL, LDL subdivided into
three subclasses (large, medium, small) and HDL subdivided
into four subclasses (very large, large, medium, small). The
platform also elucidates the constituents within each lipoprotein
particle type (triacylglycerol, total cholesterol, non-esterified
cholesterol and cholesteryl ester levels and phospholipid
concentrations). Fatty acids, amino acids, glycolysis-related
metabolites, ketone bodies and inflammatory markers are also
measured. Sixteen analytes, measured using conventional lab-
oratory platforms (ESM Table 1), were selected on the basis of
hypothesised/established association with type 2 diabetes,
GDM or insulin resistance [19]. These were markers of glucose
homeostasis (HbA1c, fructosamine, insulin, C-peptide), liver-
associated markers (alanine aminotransferase [ALT], aspartate
aminotransferase [AST], γ-glutamyl transferase [gGT], sex
hormone binding globulin [SHBG]), adipokines (adiponectin,
leptin), inflammatory and endothelial markers (high-sensitivity
C-reactive protein [hs-CRP], IL-6, tissue plasminogen activator
[tPA] antigen and ferritin), vitamin D and human placental
lactogen (hPL).
All analytes were evaluated at both time points, except
vitamin D, hPL and HbA1c (time point 1) and insulin resis-
tance indices (time point 2: HOMA2-IR, updated HOMA of
insulin resistance; HOMA2-%S, updated HOMA of insulin
sensitivity; HOMA2-%B, updated HOMA of steady-state be-
ta cell function [20]). Glucose measurements as part of the
OGTT were not included in the analysis at time point 2 as
these are integral to the diagnosis of GDM.
Statistical analysis Analytes were checked for normality;
those with non-parametric distribution were log-transformed.
Measures were checked for variation for gestational age at
sampling and transformed into corrected centiles where
required. Demographic characteristics were compared be-
tween groups using Student’s t test or Mann–Whitney tests
for continuous data and χ2 tests for categorical data as appro-
priate. Analyte data at time points 1 and 2 were compared
between women who developed GDM (GDM women) and
those who did not (non-GDM women). Associations with
GDM status were undertaken using univariate and multivari-
ate regression analyses. SD difference between GDM and
non-GDM women is reported to enable comparison across
multiple measures, originally recorded in differing units. An
a priori decision based on known associations was used to
identify confounders for multivariate analyses; these were
BMI, parity, ethnicity and age. Intervention allocation was
additionally included in the model at time point 2 to adjust
for any intervention effect on the analytes. A false discovery
rate (FDR) approach [21] was employed to reduce the proba-
bility of false-positive findings and minimise the effects of
multiple testing. Statistical significance was assumed if
FDR-corrected p values fell below 0.05.
Sensitivity analyses were performed, removing outliers
(measures outside four SDs) and restricting measurements at
both time points to shorter gestational windows; 15+0 to
17+6 weeks’ and 26+0 to 28+6 weeks’. In addition, a sen-
sitivity analysis comparing available data in the whole
cohort to complete case data was undertaken.
Statistical analyses were carried out using Stata software,
version 14.2 (StataCorp, College Station, TX, USA).
Results
Of the 1555 women in the UPBEAT trial, 646 who provided
blood samples and for whom complete analyte data were
available were included (median BMI 35.2 kg/m2).
Participant characteristics are given in Table 1. Women who
developed GDM (n = 198) had higher BMI and systolic blood
pressure and were older than those who did not develop
GDM.
Univariate analysis identified numerous differences be-
tween obese GDM and non-GDM women. After adjustment
for potential confounders (BMI, ethnicity, parity, age and in-
tervention allocation at time point 2), a similar magnitude of
association persisted for most analytes (ESM Tables 2, 3).
Association of analytes with GDM, illustrated using differ-
ence in SD between GDM and non-GDM women, for the
two time points following multivariate analysis are shown in
Figs 1, 2, 3. Figure 1 details total lipids in all subclasses,
particle size, apolipoproteins and lipoprotein constituents
(cholesterol, triacylglycerols and phospholipids) in major li-
poprotein groups. Figure 2 gives additional information about
constituents in lipoprotein subclasses. Figure 3 details fatty
acids, glycolysis-related metabolites, amino acids, ketone
bodies and other analytes. Concentrations of these analytes
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at time points 1 and 2 are shown in ESM Table 4 and ESM
Table 5, respectively.
Lipoproteins Both before diagnosis and at the time of diag-
nosis, GDM women (compared with non-GDM women) had
higher total lipids in all VLDL subclasses apart from very
small (extremely large, very large, large, medium and small)
(Fig. 1). Analysis of constituents demonstrated that this was
attributable to greater total cholesterol in VLDL (comprising
non-esterified cholesterol and cholesteryl esters) in all but the
small VLDL subparticles (non-esterified cholesterol alone),
together with a higher triacylglycerol concentration in all
VLDL subclasses at both time points. VLDL phospholipid
content followed a similar pattern: higher in all VLDL sub-
classes except very small VLDL (Fig. 2).
Prior to diagnosis, total lipids in small HDL were greater in
GDMwomen, a consequence of higher concentrations of non-
esterified cholesterol, triacylglycerols and phospholipids.
Non-esterified cholesterol concentration was lower in the
large HDL subclass and phospholipid concentrations were
lower in the very large HDL subclass. As well as VLDL,
GDM was positively associated with triacylglycerols in IDL,
small LDL and medium and small HDL. Similar differences
between GDM and non-GDM women were evident at time
point 2, the only additional differences being in cholesterol
content of some IDL, LDL and HDL subclasses (Figs 1, 2).
GDM was positively associated with apolipoprotein B and
B/A1 ratio at time point 1 but a negative association with
apolipoprotein A1 was evident only at the time of diagnosis.
VLDL particles were bigger and HDL smaller in GDM
women at both time points. LDL particles were larger at time
point 2 (Fig. 1).
Fatty acids In GDM compared with non-GDM women, total
fatty acids were higher at time point 1 and were marginally
increased at the time of diagnosis (Fig. 3). Unsaturation was
lower and monounsaturated fatty acid and saturated fatty acid
concentrations were greater at both time points. When
expressed as proportions of total fatty acids, polyunsaturated
fatty acids (linoleic acid, omega-6) were reduced, whereas
monounsaturated fatty acids were increased. At time point 2,
a decreased proportion of docosahexaenoic acid and increased
proportion of saturated fatty acids both reached significance in
GDM women.
Table 1 Characteristics of GDM
women vs non-GDM women Characteristic No GDM (n = 448) GDM (n = 198) p value
a
Ethnicity 0.35
African 59 (13.2) 38 (19.2)
Afro-Caribbean 27 (6.0) 14 (7.1)
South Asian 33 (7.4) 14 (7.1)
European 290 (64.7) 116 (58.6)
Other 39 (8.7) 16 (8.1)
Parity 0.85
Nulliparous 193 (43.1) 89 (44.9)
Multiparous 255 (56.9) 109 (55.1)
Current smoking status 0.53
Non-smoker 420 (93.8) 183 (92.4)
Smoker 28 (6.3) 15 (7.6)
Age, years 30.5 ± 5.6 31.5 ± 4.6 0.027
Height, cm 164.2 ± 6.6 163.6 ± 7.1 0.29
Weight, kg 95.5 (87.1–105.8) 96.6 (88.9–107.0) 0.17
BMI, kg/m2 34.7 (32.6–38.5) 36.1 (33.0–39.4) <0.001
Systolic BP, mmHgb 116.4 ± 10.8 120.6 ± 10.7 <0.001
GA at time point 1, weeks 16.9 ± 1.1 17.0 ± 1.0 0.47
GA at time point 2, weeks 27.7 ± 0.7 27.8 ± 0.6 0.48
Randomisation 0.63
Control 226 (50.4) 104 (52.5)
Intervention 222 (49.6) 94 (47.5)
Data are shown as number (%), mean ± SD or median (interquartile range)
a p value from χ2 , Student’s t test or Mann–Whitney test as appropriate
bMissing data: systolic BP for 12 individuals
GA, gestational age
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Fig. 2 Differences in lipoprotein subclass constituents between GDM
and non-GDM women at time points 1 and 2. Lipoprotein subclass con-
stituent contents were measured at time points 1 and 2. Data points show
the SD difference between GDM and non-GDM women prior to
diagnosis of GDM (time point 1) and at the time of OGTT (time point
2). Positive associations with GDM are shown to the right, negative
associations are shown to the left. Closed black circles represent FDR-
corrected p values of <0.05. Free cholesterol, non-esterified cholesterol
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Fig. 1 Differences in lipoprotein particle groups between GDM and non-
GDM women at time points 1 and 2. Total lipids in all lipoprotein sub-
classes, particle size, apolipoproteins and total lipoprotein constituents
were measured at time points 1 and 2. Data points show the SD
difference between GDM and non-GDM women prior to diagnosis
of GDM (time point 1) and at the time of OGTT (time point 2).
Positive associations with GDM are shown to the right, negative
associations are shown to the left. Closed black circles represent
FDR-corrected p values of <0.05. Free cholesterol, non-esterified
cholesterol; PC, phosphatidylcholines; PG, phosphoglycerides; SM,
sphingomyelins; TG:PG, triacylglycerol:phosphoglyceride
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Glucose homeostasis At time point 1, glucose and HbA1c
were higher in GDM women and, at both time points,
fructosamine, C-peptide and insulin were raised (Fig. 3).
Glycolysis intermediate pyruvate and tricarboxylic acid
(TCA) cycle intermediate citrate concentrations were also
higher but lactate was not different between groups at either
time. Insulin indices as assessed by HOMA scores indicated
marked reduction in beta cell function and insulin sensitivity
as well as increased insulin resistance in GDM women at the
time of diagnosis.
Amino acids and ketone bodiesBranched-chain amino acids
(BCAA) valine, leucine and isoleucine were higher in GDM
women than in non-GDMwomen at time points 1 and 2 (Fig. 3).
Of the aromatic amino acids, phenylalanine was raised and
tyrosine additionally increased in GDM women at time point
2. Alanine was increased at time point 2 and acetoacetate was
increased in GDM women at both time points.
Liver, adipokines and inflammatory markers Of the liver
markers, gGT was markedly higher in GDM women com-
pared with non-GDM women prior to and at the time of diag-
nosis, whereas SHBG was lower at both time points (Fig. 3).
AST and ALT were not associated with GDM status.
Adiponectin concentrations were lower in GDM women
at both time points but leptin showed no association. The
low-grade inflammatory marker glycoprotein acetyls (GlycA)
was increased at both time points whereas tPA-antigen was
raised only at time point 2 in GDM compared with non-GDM
women.
Sensitivity analyses Sensitivity analyses (excluding outliers
falling outside 4 SD and using a restricted time window) iden-
tified minor differences in very few metabolites (9 at time
point 1, 20 at time point 2) when compared with the main
analyses (ESM Tables 2, 3).
When we repeated analyses using all available data (mean
number of women at time point 1 = 925, mean number at time
point 2 = 830), apart from one metabolite the results were the
same as those presented in the main analyses (complete case
analyses). Data are available on request.
Discussion
Using an approach combining targeted NMR metabolomics
and established metabolic risk factors in blood from pregnant
women, we have described novel metabolic profile differences
in obese women who develop GDM. There was a marked sim-
ilarity in differential patterns found pre-diagnosis of GDM and
at the time of diagnosis. Of the few previous reports of
dysglycaemia in pregnancy in which the serum/plasma
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Fig. 3 Differences in fatty acids, amino acids, glycaemic and other
markers between GDM and non-GDM women at time points 1 and 2.
Fatty acids, glycolysis-related metabolites, amino acids, ketone bodies
and inflammatory and other markers were measured at time points 1
and 2. Data points show the SD difference between GDM and non-
GDM women prior to diagnosis of GDM (time point 1) and at the time
of OGTT (time point 2). Positive associations with GDM are shown to
the right, negative associations are shown to the left. Closed black circles
represent FDR-corrected p values of <0.05. DHA, docosahexaenoic acid,
22:6; LA, linoleic acid, 18:2; MUFA monounsaturated fatty acids, 16:1,
18:1; PUFA polyunsaturated fatty acids; SFA Saturated fatty acids; TFA,
total fatty acids
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metabolome has been described, none has previously addressed
GDMconfined to obesewomen and recent reports have focused
on moderate hyperglycaemia [8, 9].
As anticipated and in line with the diagnosis of GDM,
obese women had raised dysglycaemic markers, including
HbA1c, fructosamine and insulin, and these were raised before
diagnosis. Adiponectin, recently identified as a predictor of
GDM in women of heterogeneous BMI [22], was markedly
lower at both the pre- and peri-diagnosis time points in the
obese GDM women compared with the non-GDM women in
this cohort.
In accordance with insulin resistance states in non-pregnant
individuals [23], the metabolome in GDM revealed a complex
change in the metabolic profile. In addition to dysregulation of
glucose metabolism, we have demonstrated that obese GDM
women, compared with obese non-GDM women, exhibit
exaggerated dyslipidaemic profiles that complement our un-
derstanding of the effects of insulin resistance on the lipid
metabolism pathways in pregnant women [1, 4].
As normal pregnancy progresses, physiological perturba-
tions to glycaemic and lipid pathways caused by increasing
insulin resistance are well documented: early lipogenesis
(anabolic phase) followed by lipolysis (catabolic phase) is
recognised in normal-weight women [1]. Using the same
NMR method as the present study, Wang et al reported first
trimester lipoprotein concentrations similar to those seen in
non-pregnant women in normal non-obese pregnancies,
followed by marked increases in lipoprotein constituents, in-
cluding triacylglycerols, in the second and third trimesters [4].
In contrast, obese women demonstrate reduced insulin sensi-
tivity from an earlier gestation, particularly with regard to lipid
metabolism [1]. Using non-NMR methods, others have re-
ported dyslipidaemia in obese vs normal-weight pregnancy,
including raised total and LDL-cholesterol, lower HDL-
cholesterol and raised triacylglycerols from the first trimester
[24–27]. The exaggerated dyslipidaemia in obese women pri-
or to and at the time of diagnosis of GDM in the present study
suggests exaggeration of these metabolic processes, reflecting
enhanced insulin resistance in adipose tissue and reduced sup-
pression of lipolysis [28]. Potentially compounded by obesity-
related higher levels pre-pregnancy, excess fatty acids are thus
available for hepatic triacylglycerol synthesis and secretion as
VLDL lipoproteins from early gestation. Indeed, all VLDL
subclasses were richer in triacylglycerols in GDM compared
with non-GDM women, and triacylglycerols were higher in
IDL, small LDL and medium and small HDL subclasses,
building on reports of triacylglycerol enrichment of VLDL,
LDL and HDL in normal pregnancy [29]. The increased con-
centrations of triacylglycerol-rich lipoproteins may also result
from decreased adipose tissue lipoprotein lipase activity, sec-
ondary to greater insulin resistance, leading to reduced clear-
ance of triacylglycerol-rich lipoproteins [29]. Cholesteryl ester
transferase protein (CETP), the activity of which is enhanced
in insulin resistance, likely contributes to the triacylglycerol
enrichment of the smaller lipoprotein particles [30].
Furthermore, as observed particularly in later pregnancy sam-
ples, the role of CETP is corroborated by increased concen-
trations of cholesteryl esters in VLDL and reduced quantities
in LDL and HDL subclasses [30].
Among the HDL subclasses, the smallest had a different
profile from the larger particles, being increased in GDM
women. While characterisation of size distribution is di-
vergent between methodological platforms, others using
the same NMR platform in a cohort of 9399 Finnish
men have reported an abundance of small HDL particles
and reduced amounts of larger HDL particles in association
with glucose intolerance [23].
Although phospholipid enrichment followed a similar pat-
tern to triacylglycerols, interpretation is limited without fur-
ther characterisation of these complex lipid subgroups.
There were few consistent changes in either LDL or IDL
constituent concentrations in GDM compared with non-GDM
women. Contrary to a previous observation in weight-
heterogeneous women [31], a relationship between GDM
and reduced-sized LDL particles was not observed; indeed,
at the time of diagnosis, obese women with GDM exhibited
larger LDL particles.
Despite the difference in fasting state between the two
points of measurement, similar patterns in fatty acid differ-
ences between GDM and non-GDM women were evident.
The fatty acid profile in GDM obese women was similar to
that seen in a previous study of dysglycaemia in Finnish men
using this platform [32]: a predominance of saturated and
monounsaturated fatty acids and lower concentrations of poly-
unsaturated fatty acids in GDM vs non-GDM women. This
may reflect the unhealthy dietary pattern termed ‘processed
foods’ that we recently reported amongst women who devel-
oped GDM in the same cohort [33].
Beyond recognised markers of dysglycaemia (e.g. HbA1c
and fructosamine) obese GDM women demonstrated meta-
bolic patterns consistent with perturbed energy pathways
and increased fuel availability. These included elevated pyru-
vate and alanine (both substrates of carbohydrate metabo-
lism), raised acetoacetate (likely secondary to unregulated fat-
ty acid oxidation and/or increased metabolism of BCAA) and
higher citrate (an early intermediate of the TCA cycle). The
observed increase in alanine concurs with previous
metabolomic studies of mild hyperglycaemia in pregnant
women of heterogeneous BMI from the Hyperglycemia and
Adverse Pregnancy Outcome (HAPO) cohort [8, 9].
As described in weight-heterogeneous GDM women [34]
and in recent studies [35] including HAPO [8, 9], BCAA
were higher in GDM women, implicating a predominant
influence of insulin resistance as opposed to obesity. Whether
elevation of BCAA reflects cause or effect is unclear; the
mechanism may relate to reduced branch-chain α-ketoacid
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dehydrogenase activity as implicated in insulin resistance in
non-pregnant states, although multiple pathological processes
may be involved [36–38]. Consistent with some reports,
higher levels of aromatic amino acids were associated with
GDM–phenylalanine at both time points and tyrosine later in
pregnancy [9, 35]. In contrast, recent studies of the metabo-
lome in normal pregnancy and GDM amongst weight-
heterogeneous women demonstrate a complex picture of
amino acids across gestation and found no obvious relation-
ship with gestational insulin resistance [4, 35].
gGT was higher in GDM, although other markers of a
hepatic process such as fatty liver infiltration (ALT and
AST) were not elevated. There is no obvious mechanism,
but this could reflect increased oxidative stress, previously
linked to GDM [39]. Lower SHBG, associated with insulin
resistance [40] and GDM [41], was noted in obese GDM
women at both time points, adding to the evidence that low
SHBG reflects insulin resistance rather than obesity per se. In
contrast to adiponectin, leptin, although reported to be raised
in GDM amongst weight-heterogeneous women [42], was not
associated with GDM in the obese women. This may reflect
habitually high leptin levels in association with obesity, and
non-specificity as a GDM marker.
Although inflammatory pathways are commonly implicat-
ed in GDM pathogenesis [43], most markers of inflammation
measured were not associated with GDM. One notable excep-
tion was GlycA, a complex NMR signal of N-acetyl methyl
group protons of mobile glycan residues of glycoproteins
[44], which was markedly higher in obese GDM women at
both time points. Plasma glycoproteins are predominantly
acute-phase proteins and GlycA is associated with conditions
associated with an inflammatory response, including type 2
diabetes [45]. This novel observation suggests that GlycA
might also be a useful marker for GDM.
This study has several strengths and limitations. To our
knowledge, this is the first study to assess a range of metabo-
lites associated with GDM in a large cohort of obese pregnant
women longitudinally in pregnancy. We are not aware of any
study with a similar or larger sample size in obese pregnant
women with accurately (universal OGTT) diagnosed GDM
and multiple metabolites assessed both in early and mid-preg-
nancy, and acknowledge that these results should be treated
with some caution until replication is possible. This is also the
first time that a targeted NMR approach providing detailed
lipoprotein and subclass constituent information has ad-
dressed GDM. Importantly, BMI was assessed early in preg-
nancy (at time point 1) prior to fetal growth and with
standardised measures in the research setting.
As the trial was designed before recognition of ‘early
GDM’, women were not systematically identified as such, or
removed, and we acknowledge this as a possible limitation.
However, poor correlation between early and later diagnostic
testing is recognised [46, 47], exemplified by a recent study of
obese women, in which GDM prevalence of ~20% was re-
corded (OGTT at 24–28 weeks) despite removal of those di-
agnosed by early OGTT using IADPSG thresholds [48]. This
suggests that, despite some overlap, many women diagnosed
with GDM at 24–28 weeks’ gestation would not have been
classified as GDM early in pregnancy.
A further limitation of the study was that analytes were
measured in differing prandial states at the two time points.
Samples were collected from non-fasting participants at time
point 1, and this could influence some metabolites; however,
differential patterns at each time point were not affected. There
was also no lean control group comparison.
We recognise that further information could be gained from
analysis of the metabolome using mass spectrometry.
Particularly interesting, would be non-esterified fatty acids,
acylcarnitines and phosphatidylcholine subspecies.
Although highly correlated, NMR metabolite absolute
values showed small negative biases compared with conven-
tional platforms for glucose and commonly measured lipids
(e.g. total cholesterol) (data not shown). Thus, direct compar-
ison with clinical thresholds is inadvisable.
In summary, this study has increased our knowledge of met-
abolic pathways in GDM amongst obese pregnant women as
assessed by NMR spectroscopy and traditional platforms. It
adds to observations in which the metabolome as measured by
mass spectrometry was investigated in mildly hyperglycaemic
women from the HAPO study (BMI 29.0 kg/m2; SD 4.89, at
OGTT) [8]. In the present study, we have defined differences in
the metabolic profile of GDM specific to obese women. The
importance lies in the increasing prevalence of obesity and the
current practice of treating all obese women as of equal risk for
GDM. The metabolic profiling described has clearly identified
that those women who later develop GDM have a similar dif-
ferential profile earlier in gestation as is evident at the time of
GDM diagnosis, when compared with non-GDM women. In
addition to classic insulin resistancemarkers as described recent-
ly by others [49], we document a distinct lipid profile
characterised by differing lipoprotein subclasses and their con-
stituents. This strongly supports the suggestion that, at least in
obese women, the metabolic perturbations of insulin resistance
predate GDM diagnosis in the second trimester by many weeks.
It follows that diagnosis using glucose thresholds from an
OGTT between 24 and 28 weeks fails to identify affected preg-
nancies in a timely fashion and supports the recent observation
that excessive fetal growth precedes the diagnosis of GDM [50].
A diagnostic approach that utilises other metabolic abnormali-
ties rather than or in addition to glucose, a later manifestation of
abnormal insulin resistance and function, could potentially im-
prove treatment and outcomes.
This study provides new insight into the metabolic changes
associated with GDM in obese women. By demonstrating differ-
ences in the metabolic phenotype arising earlier in gestation,
encompassing diverse pathways in affected women, this study
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allows new targets for effective intervention and prevention to be
identified. The findings strongly support diagnosis of GDM in
obese women earlier in gestation than currently practised, either
using theOGTTwith new validated thresholds or by means of
more biologically relevant risk assessment tools [10].
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